Skip to main content

Market Overview

Biofrontera Raises $8.9M Via Equity Offering

  • Biofrontera AG (NASDAQ: BFRApriced an underwritten public offering of around 1.3 million ADS at $6.68 per ADS, raising gross proceeds of approximately $8.9 million. The offer price represents a discount of 5% from the last close price of $7.04 on Tuesday.
  • Each ADS represents two of BFRA's ordinary shares.
  • The offering will close by February 26.
  • This offer is part of concurrent preemptive rights offered to the company's ordinary shares holders of around 8.9 million ordinary shares at €2.75 per share.
  • Proceeds will be used for regulatory approval for expanded use of its lead product Ameluz, in the U.S. to basal cell carcinoma, acne, and actinic keratoses, complete the development of a larger BF-RhodoLED lamp, and for general corporate purposes.
  • The Benchmark Company is acting as the managing underwriter with Lake Street Capital Markets acting as co-manager for the offering.
  • Price Action: BFRA is down 1.6% at $6.91 in premarket trading on the last check Wednesday.

Related Articles (BFRA)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Offerings General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at